The Asia Pacific Leadless Pacemakers Market would witness market growth of 16.7% CAGR during the forecast period (2023-2030).
The ability to avoid a number of problems associated with transvenous pacemakers and conventional leads, including pocket infections, hematoma, lead fractures, and lead dislodgment, is what has prompted the adoption of leadless pacemakers.
Moreover, leadless pacemakers have undergone significant technological advancements, driving the market's growth. These innovations include improvements in battery life, remote monitoring capabilities, and enhanced programming features. Patients can now benefit from longer-lasting devices, and healthcare providers can remotely monitor patients' cardiac data, leading to more proactive and personalized care.
In addition to these technological advancements, the market has been marked by increasing clinical evidence supporting the safety and efficacy of these devices. A growing body of research and clinical studies has demonstrated the comparable performance of leadless pacemakers to traditional devices, reassuring healthcare providers and patients about their effectiveness. This robust clinical foundation has accelerated the adoption of leadless pacemakers across healthcare settings.
According to the National Library of Medicine, the reported prevalence of AF in Asia Pacific countries varies from 0.49% to 5.4%. The majority of AF in those aged >70 or 80 years was 4.6%–8.2%. The prevalence of AF progressively increased more than twofold over the last 10 years and is significantly greater in men than in women for all years. AF prevalence in Thailand has been reported to be 1.9% for those aged ≥65 years and 2.2% in rural areas for those aged ≥60 years. AF prevalence in Korea is expected to be 5.8% in 2060 and 4.0% in Taiwan by 2050.
The same source also stated that after industrialization, the availability of processed foods and Westernization of dietary trends have resulted in an estimated 40.9% overweight/obese prevalence among adults in the Asia–Pacific region, with an estimated economic impact of up to 12% of total health care spending on obesity or related diseases. The rising prevalence of obesity in Asia has led to an increased incidence of heart-related conditions, including bradycardia and other arrhythmias. Obesity is a known risk factor for heart disease, as it can lead to structural changes in the heart and disrupt the electrical conduction system. Consequently, more individuals with obesity are at risk of requiring cardiac pacing, which has contributed to the demand for leadless pacemakers in this region.
The China market dominated the Asia Pacific Leadless Pacemakers Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $43,332.7 Thousands by 2030. The Japan market is registering a CAGR of 16% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 17.4% during (2023 - 2030).
Based on Type, the market is segmented into Micra Transcatheter Pacing System, and Others. Based on End-use, the market is segmented into Hospitals, and Outpatient Facilities. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Global Leadless Pacemakers Market is Predict to reach $827.7 Million by 2030, at a CAGR of 15.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Lepu Medical Technology Co., Ltd, Integer Holdings Corporation, MicroPort Scientific Corporation, Osypka AG, Terumo Corporation, and EBR Systems, Inc.
By Type
By End-use
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 